Five Prime to Present Preclinical Research Data at 2017 AACR Annual Meeting

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2017 -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing innovative immuno-oncology protein therapeutics, today announced that it will feature three new preclinical research  poster presentations during the 2017 American Association for Cancer Research (AACR) Annual Meeting, being held April 1 - 5, 2017, in Washington, D.C.

Abstract Number and Title: #613, “Development of FPA154, a Novel Tetravalent Anti-GITR Antibody, for the Treatment of Solid Tumors”
Session Title: T-cell Immunity to Cancer: New Progress
Session Date and Time: Sunday, April 2, 2017, 1 - 5 p.m.
Location: Convention Center, Halls A-C, Poster Section 26, Poster Board Number: 17

Abstract Number and Title: #1599, “Antibody-Based Inhibition of CSF-1R as a Component of Combination Immunotherapy in Preclinical Models”
Session Title: Cytokines: The First Modern Immunotherapies
Session Date and Time: Monday, April 3, 2017, 8 a.m. - 12 p.m.
Location: Convention Center, Halls A-C, Poster Section 26, Poster Board Number: 7

Abstract Number and Title: #2633, “Identification of Novel T Cell Co-Inhibitory and Co-Stimulatory Receptors from Screening a Comprehensive Library of Extracellular Proteins”
Session Title: Checkpoints 2: Small-Molecule Inhibitors
Session Date and Time: Monday, April 3, 2017, 1- 5 p.m.
Location: Convention Center, Halls A-C, Poster Section 25, Poster Board Number: 22

About Five Prime

Five Prime Therapeutics, Inc. discovers and develops innovative therapeutics to improve the lives of patients with serious diseases. Five Prime's comprehensive discovery platform, which encompasses virtually every medically relevant extracellular protein, positions it to explore pathways in cancer, inflammation and their intersection in immuno-oncology, an area with significant therapeutic potential and a growing focus of the company's R&D activities. Five Prime has entered into strategic collaborations with leading global pharmaceutical companies and has promising product candidates in clinical and late preclinical development. For more information, please visit www.fiveprime.com.

Cautionary Note on Forward-looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) are intended to identify forward-looking statements. These forward-looking statements are based on Five Prime's expectations and assumptions as of the date of this press release. Each of these forward-looking statements involves risks and uncertainties. Actual results may differ materially from these forward-looking statements. Factors that may cause actual results to differ from those expressed or implied in the forward-looking statements in this press release are discussed in Five Prime's filings with the U.S. Securities and Exchange Commission, including the "Risk Factors" contained therein. Except as required by law, Five Prime assumes no obligation to update any forward-looking statements contained herein to reflect any change in expectations, even as new information becomes available.

CONTACTS:

Heather Rowe
Investor Relations
415-365-5737
[email protected]

Amy Kendall
Corporate Communications
415-365-5776
[email protected]